TY - JOUR
T1 - Reversal of a Treatment-Resistant, Depression-Related Brain State with the Kv7 Channel Opener Retigabine
AU - Feng, Mengyang
AU - Crowley, Nicole A.
AU - Patel, Akshilkumar
AU - Guo, Yao
AU - Bugni, Sierra E.
AU - Luscher, Bernhard
N1 - Funding Information:
This publication was made possible by grants MH099851 to B.L. from the National Institutes of Mental Health (NIMH), a seed grant from the Social Science Research Institute (to B.L. and N.A.C) and a training grant (T32AI074551) from the National Institute of Allergy and Infectious Diseases (NIAID). Its contents are solely the responsibility of the authors and do not necessarily represent the views of the funding agencies. The authors declare no competing financial interests.
Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/5/15
Y1 - 2019/5/15
N2 - Neuroinflammation is associated with increased vulnerability to diverse psychiatric conditions, including treatment-resistant major depressive disorder (MDD). Here we assessed whether high fat diet (HFD) induced neuroinflammation may be suitable to model a treatment-resistant depressive-like brain state in mice. Male and female mice were fed a HFD for 18 weeks, followed by quantitation of glucose tolerance, inflammatory markers of brain tissue (TNFα IL-6, IL-1β Iba-1), neural excitability in the prelimbic cortex (PLC), as well as assessment of emotional reactivity and hedonic behavior in a battery of behavioral tests. In addition, we assessed the behavioral responsiveness of mice to fluoxetine, desipramine, ketamine, and the Kv7 channel opener and anticonvulsant retigabine. HFD exposure led to glucose intolerance and neuroinflammation in male mice, with similar but non-significant trends in females. Neuroinflammation of males was associated with anxious-depressive-like behavior and defects in working memory, along with neural hyperexcitability and increased I h currents of pyramidal cells in the PLC. The behavioral changes were largely resistant to chronic treatment with fluoxetine and desipramine, as well as ketamine. By contrast, retigabine (also known as ezogabine) normalized neural excitability and I h currents recorded from slices of HFD-treated animals and significantly ameliorated most of the behavioral impairments, without effects in control diet exposed animals. Thus, treatment resistant depressive-like brain states that are associated with chronic neuroinflammation may involve hyperexcitability of pyramidal neurons and may be effectively treated by retigabine.
AB - Neuroinflammation is associated with increased vulnerability to diverse psychiatric conditions, including treatment-resistant major depressive disorder (MDD). Here we assessed whether high fat diet (HFD) induced neuroinflammation may be suitable to model a treatment-resistant depressive-like brain state in mice. Male and female mice were fed a HFD for 18 weeks, followed by quantitation of glucose tolerance, inflammatory markers of brain tissue (TNFα IL-6, IL-1β Iba-1), neural excitability in the prelimbic cortex (PLC), as well as assessment of emotional reactivity and hedonic behavior in a battery of behavioral tests. In addition, we assessed the behavioral responsiveness of mice to fluoxetine, desipramine, ketamine, and the Kv7 channel opener and anticonvulsant retigabine. HFD exposure led to glucose intolerance and neuroinflammation in male mice, with similar but non-significant trends in females. Neuroinflammation of males was associated with anxious-depressive-like behavior and defects in working memory, along with neural hyperexcitability and increased I h currents of pyramidal cells in the PLC. The behavioral changes were largely resistant to chronic treatment with fluoxetine and desipramine, as well as ketamine. By contrast, retigabine (also known as ezogabine) normalized neural excitability and I h currents recorded from slices of HFD-treated animals and significantly ameliorated most of the behavioral impairments, without effects in control diet exposed animals. Thus, treatment resistant depressive-like brain states that are associated with chronic neuroinflammation may involve hyperexcitability of pyramidal neurons and may be effectively treated by retigabine.
UR - http://www.scopus.com/inward/record.url?scp=85063035491&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063035491&partnerID=8YFLogxK
U2 - 10.1016/j.neuroscience.2019.03.003
DO - 10.1016/j.neuroscience.2019.03.003
M3 - Article
C2 - 30858110
AN - SCOPUS:85063035491
SN - 0306-4522
VL - 406
SP - 109
EP - 125
JO - Neuroscience
JF - Neuroscience
ER -